Scientists test new cancer vaccine against melanoma

September 6, 2018, The Scripps Research Institute
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

An experimental cancer vaccine that boosts the immune system's ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumors, scientists reported recently in the Proceedings of the National Academy of Sciences.

The researchers demonstrated that adding a molecule called Diprovocim to a can draw cancer-fighting cells to tumor sites. Their experiments in with melanoma suggest these vaccines could increase chances of recovery in cases where a drug therapy alone is not working.

"This co-therapy produced a complete response—a curative response—in the treatment of melanoma," says Scripps Research Professor Dale Boger, Ph.D., who co-led the study with Nobel laureate Bruce Beutler, MD, of UT Southwestern.

The vaccine also prompts the immune system to fight tumor cells should they ever return, a capability that could prevent cancer recurrence. "Just as a vaccine can train the body to fight off external pathogens, this vaccine trains the immune system to go after the tumor," Boger explains.

Developed by Boger and Beutler, Diprovocim works as an "adjuvant," a molecule added to a vaccine to fire up the body's immune response. The molecule is easy to synthesize in the lab and easy to modify, which makes it attractive for use in medicine.

The new research shows that adding Diprovocim to a vaccine targeting cancer cells can have dramatic results.

The researchers tested the vaccine design on mice with a form of notoriously aggressive melanoma. All mice in the experiment were given the anti- anti-PD-L1. The mice were then split into three group: eight received the , eight received the cancer vaccine plus Diprovocim, and eight received the cancer vaccine plus an alternative adjuvant called alum.

The researchers observed a 100 percent survival rate over 54 days in the mice given the cancer vaccine and Diprovocim. This was in contrast to a zero percent survival rate in mice given only the cancer vaccine and a 25 percent survival rate in mice given the cancer vaccine with alum.

"It was exciting to see the vaccine working simultaneously with a cancer immunotherapy like anti-PD-L1," says Boger.

Further experiments showed that using Diprovocim as an adjuvant boosts the vaccine's cancer-fighting potential by stimulating the immune system to make cells called tumor-infiltrating leukocytes.

When the scientists tried to re-establish the tumor in these mice, "it wouldn't take," Boger says. "The animal is already vaccinated against it."

Boger says it is encouraging to see that the vaccine with Diprovocim does not need to be injected directly into a tumor. Instead, the researchers gave it as an intramuscular injection away from the main site. The vaccination did require two doses given seven days apart.

Going forward, the researchers plan to do further pre-clinical testing with this and study how it works in combination with other therapies.

Boger and Beutler have acknowledged a financial interest in Tollbridge Therapeutics, LLC, which has licensed the patent for Diprovocim.

The study "Adjuvant effect of the novel TLR1/2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice," was supported by the National Institutes of Health (grant AI25581) and the Lyda Hill Foundation.

Explore further: Stem cell vaccine immunizes lab mice against multiple cancers

More information: Ying Wang et al, Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1809232115

Related Stories

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

DNA-based vaccine treatment for colorectal cancer to undergo first human study

May 22, 2018
For the first time in humans, researchers will test a two-pronged approach to treat advanced stage colorectal cancer (CRC), potentially increasing life expectancy. Combining a DNA vaccine, which boosts the body's immune response ...

Brain cancer vaccine effective in some patients

May 31, 2018
Most people with the deadly brain cancer glioblastoma die less than 18 months after diagnosis. But a multicenter clinical trial of a personalized vaccine that targets the aggressive cancer has indicated improved survival ...

New vaccine technique effectively fights breast cancer in mice

November 30, 2017
A new vaccine technique can fight a certain type of breast cancer in mice. So-called HER2-positive breast cancer accounts for between 20 and 30 per cent of all cases of breast cancer in humans. Researchers from the University ...

Novel cancer vaccine strategy blocks death of tumor-specific cytotoxic T cells

May 1, 2018
New research published in Cancer Immunology Research by Drs. Esteban Celis and Hussein Sultan of the Georgia Cancer Center at Augusta University could serve as the stepping-stone in constructing vaccines with a greater likelihood ...

Recommended for you

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

September 24, 2018
Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.